Travere Therapeutics (NASDAQ:TVTX) CFO Sells $101,743.65 in Stock

Key Points

• CFO Christopher Cline sold 2,181 shares on May 5 at an average price of $46.65 for $101,743.65 under a pre‑arranged Rule 10b5‑1 plan to cover tax withholding, leaving him with 118,968 shares (a 1.80% reduction).
• Travere beat Q1 EPS expectations (reported $0.05 vs. consensus −$0.24) and saw revenue rise 55.6% year‑over‑year to $127.2M (below the $136.2M estimate), but the company remains unprofitable with negative margins.
• Analysts have grown more bullish—TD Cowen raised its target to $60, Wells Fargo to $50 and Citigroup to $59, producing a consensus "Moderate Buy" target near $47.83—while insider selling continues (Director Roy Baynes sold 9,750 shares under a 10b5‑1 plan).

Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) CFO Christopher Cline sold 2,181 shares of the firm's stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $46.65, for a total value of $101,743.65. Following the sale, the chief financial officer directly owned 118,968 shares of the company's stock, valued at $5,549,857.20. This represents a 1.80% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Travere Therapeutics Stock Performance

Shares of TVTX traded down $0.10 during midday trading on Wednesday, reaching $44.70. 2,390,035 shares of the stock were exchanged, compared to its average volume of 2,890,153. Travere Therapeutics, Inc. has a twelve month low of $13.88 and a twelve month high of $48.61. The company has a quick ratio of 2.70, a current ratio of 3.13 and a debt-to-equity ratio of 3.16. The company has a market cap of $4.16 billion, a P/E ratio of -194.33 and a beta of 1.13. The stock's 50 day simple moving average is $32.59 and its 200 day simple moving average is $32.83.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last posted its earnings results on Monday, May 4th. The company reported $0.05 earnings per share for the quarter, topping analysts' consensus estimates of ($0.24) by $0.29. Travere Therapeutics had a negative return on equity of 26.16% and a negative net margin of 4.00%.The company had revenue of $127.20 million during the quarter, compared to the consensus estimate of $136.23 million. During the same quarter last year, the firm earned ($0.47) earnings per share. The company's revenue was up 55.6% on a year-over-year basis. On average, sell-side analysts expect that Travere Therapeutics, Inc. will post -0.16 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of TVTX. Raymond James Financial Inc. bought a new position in Travere Therapeutics in the second quarter valued at about $33,000. Fifth Third Bancorp bought a new position in Travere Therapeutics in the first quarter valued at about $35,000. First Horizon Corp bought a new position in Travere Therapeutics in the third quarter valued at about $36,000. State of Wyoming bought a new position in Travere Therapeutics in the fourth quarter valued at about $37,000. Finally, Torren Management LLC bought a new position in Travere Therapeutics in the fourth quarter valued at about $38,000.

Key Travere Therapeutics News

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: TD Cowen raised its price target from $45 to $60 and kept a "buy" rating, implying meaningful upside vs. current levels — a bullish signal from a major sell‑side shop. TD Cowen price target raise
• Positive Sentiment: Wells Fargo upgraded its target to $50 and assigned an "overweight" rating, another near‑term positive catalyst supporting higher valuation expectations. Wells Fargo price target raise
• Neutral Sentiment: HC Wainwright reiterated a "Buy" and $57 target but trimmed FY2027–FY2030 EPS forecasts slightly (e.g., FY2027 cut from $0.71 to $0.60; FY2030 to $4.59 from $4.61). The firm still models substantial multi‑year growth, so this is more of a modest forecast tweak than a change in conviction. HC Wainwright note
• Neutral Sentiment: Earnings call transcript for Q1 2026 is available — recall Travere reported a year‑over‑year revenue gain and an EPS beat in the quarter, which helped underpin recent analyst upgrades. Review the transcript for management commentary on sparsentan commercialization and margin trajectory. Q1 2026 earnings transcript
• Negative Sentiment: Director Roy Baynes sold 9,750 shares (about $431k at the sale price) under a pre‑arranged Rule 10b5‑1 plan. Insider sales can be perceived negatively by the market despite the trading plan disclosure; monitor for any further insider activity. Insider sale filing

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Citigroup lifted their target price on Travere Therapeutics from $53.00 to $59.00 and gave the stock a "buy" rating in a report on Tuesday. Wall Street Zen downgraded Travere Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Saturday, February 21st. Piper Sandler raised Travere Therapeutics from a "neutral" rating to an "overweight" rating and set a $49.00 target price for the company in a report on Tuesday, April 14th. JPMorgan Chase & Co. dropped their target price on Travere Therapeutics from $44.00 to $41.00 and set an "overweight" rating for the company in a report on Wednesday, March 25th. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of Travere Therapeutics in a report on Wednesday, January 21st. Ten investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $47.83.

About Travere Therapeutics

Travere Therapeutics, Inc NASDAQ: TVTX is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company's mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company's lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.